RESUMEN
The C-terminal two-thirds segment of integrase derived from the simian immunodeficiency virus has been cloned, expressed in Escherichia coli, and purified to greater than 95% homogeneity. The protein encompasses amino-acid residues 50-293 and contains a F185H substitution to enhance solubility. In dilute solutions at concentrations below 1 mg ml(-1), the enzyme is predominantly dimeric. At the higher concentrations (>10 mg ml(-1)) required to enable crystallization, the enzyme self-associates to form species with molecular weights greater than 200 kDa. Despite the apparent high aggregation in solution, the enzyme crystallizes from a 8%(v/v) polyethylene glycol (molecular weight 6000) solution in a form suitable for X-ray diffraction studies. The resulting single crystals belong to the space group P2(1)2(1)2(1), with unit-cell parameters a = 79.76, b = 99.98, c = 150.2 A, alpha = beta = gamma = 90 degrees and Z = 4. Under X-ray irradiation generated with a rotating-anode generator, the crystals diffract to 2.8 A resolution and allow collection of a native 3 A resolution diffraction data set.
Asunto(s)
Integrasas/química , Virus de la Inmunodeficiencia de los Simios/enzimología , Clonación Molecular , Cristalización , Dimerización , Escherichia coli , Integrasas/genética , Integrasas/aislamiento & purificación , Mutación , Polietilenglicoles , Conformación Proteica , Proteínas Recombinantes/aislamiento & purificación , Programas Informáticos , Solubilidad , Ultracentrifugación , Difracción de Rayos XRESUMEN
The N-terminal domain of the hepatitis C virus (HCV) polyprotein containing the NS3 protease (residues 1027 to 1206) was expressed in Escherichia coli as a soluble protein under the control of the T7 promoter. The enzyme has been purified to homogeneity with cation exchange (SP-Sepharose HR) and heparin affinity chromatography in the absence of any detergent. The purified enzyme preparation was soluble and remained stable in solution for several weeks at 4 degrees C. The proteolytic activity of the purified enzyme was examined, also in the absence of detergents, using a peptide mimicking the NS4A/4B cleavage site of the HCV polyprotein. Hydrolysis of this substrate at the expected Cys-Ala scissile bond was catalyzed by the recombinant protease with a pseudo second-order rate constant (k(cat)/K(M)) of 205 and 196,000 M(-1) s(-1), respectively, in the absence and presence of a central hydrophobic region (sequence represented by residues 21 to 34) of the NS4A protein. The rate constant in the presence of NS4A peptide cofactor was two orders of magnitude greater than reported previously for the NS3 protease domain. A significantly higher activity of the NS3 protease-NS4A cofactor complex was also observed with a substrate mimicking the NS4B/5A site (k(cat)/K(M) of 5180 +/- 670 M(-1) s(-1)). Finally, the optimal formation of a complex between the NS3 protease domain and the cofactor NS4A was critical for the high proteolytic activity observed.
Asunto(s)
Hepacivirus/enzimología , Proteínas/química , Serina Endopeptidasas/metabolismo , Proteínas no Estructurales Virales/química , Proteínas no Estructurales Virales/aislamiento & purificación , Técnicas de Química Analítica/métodos , Cromatografía de Afinidad , Cromatografía en Agarosa , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Poliacrilamida , Hidrólisis , Cinética , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Factores de TiempoRESUMEN
Mutant HIV-1 that expresses a Glu138-->Lys substitution in its RT [(E138K)RT] is resistant to the HIV-1-specific RT inhibitor 2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)pyrimidine (TSAO). However, cell cultures infected with this mutant were completely protected against virus-mediated destruction by micromolar concentrations of the HIV-1-specific RT inhibitors tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO), nevirapine, and bis(heteroaryl)piperazine (BHAP). In contrast, cells infected with a virus mutant that expresses a Tyr181-->Cys substitution in its RT [(Y181C)RT] were not protected by nevirapine and TIBO and were only temporarily protected by BHAP. HIV-1 mutant that emerged under the latter conditions contained a Cys181-->Ile substitution in their RT [(LC181I)RT]. This mutant proved highly resistant to all HIV-1-specific RT inhibitors tested, except for several 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) derivatives. When recombinant (C181I)RT was evaluated for susceptibility to the HIV-1-specific RT inhibitors, it was resistant to all inhibitors except the HEPT compounds. Since a (Y181F)RT HIV mutant strain was isolated from cells infected with (Y181C)RT HIV-1 and treated with BHAP, we postulate that the Ile codon was derived from a Cys-->Phe transversion mutation (TGT-->TTT), followed by a Phe-->Ile transversion mutation (TTT-->ATT).
Asunto(s)
Antivirales/toxicidad , VIH-1/efectos de los fármacos , VIH-1/enzimología , Mutación Puntual , Inhibidores de la Transcriptasa Inversa , Compuestos de Espiro , Replicación Viral/efectos de los fármacos , Secuencia de Aminoácidos , Secuencia de Bases , Benzodiazepinas/toxicidad , Línea Celular , Codón/genética , Cartilla de ADN , Transcriptasa Inversa del VIH , VIH-1/fisiología , Humanos , Imidazoles/toxicidad , Cinética , Datos de Secuencia Molecular , Nevirapina , Reacción en Cadena de la Polimerasa , Piridinas/toxicidad , Piridonas/toxicidad , ADN Polimerasa Dirigida por ARN/genética , Relación Estructura-Actividad , Timidina/análogos & derivados , Timidina/toxicidad , Uridina/análogos & derivadosRESUMEN
The human cytomegalovirus UL80 gene encodes an 80-kDa precursor polyprotein whose N-terminal 256-amino acid domain is a protease. This enzyme cleaves a specific peptide bond that results in its own release from the precursor, as well as a peptide bond near the C terminus of the viral assembly protein. The latter cleavage is apparently required for encapsidation of the viral genomic DNA and maturation of the viral capsid. A series of peptide substrates, representing the assembly protein cleavage site, was used to study the enzyme's substrate requirements and specificity. It was found that efficient cleavage minimally required the amino acid residues spanning the P4 to P4' positions. Substitution at any of these residues adversely affected the reaction. Conservation of the hydrophobic residues at P3 and P4 was essential. In addition, cleavage of a peptide representing the protease domain release site was reduced almost 100-fold relative to cleavage of the assembly protein maturation site peptide substrate.
Asunto(s)
Citomegalovirus/enzimología , ADN Viral/metabolismo , Endopeptidasas/metabolismo , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Clonación Molecular , Citomegalovirus/genética , Cartilla de ADN , Endopeptidasas/biosíntesis , Endopeptidasas/aislamiento & purificación , Genes Virales , Humanos , Cinética , Datos de Secuencia Molecular , Peso Molecular , Oligopéptidos/síntesis química , Oligopéptidos/metabolismo , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Especificidad por Sustrato , Proteínas Virales/biosíntesis , Proteínas Virales/aislamiento & purificaciónRESUMEN
The human immunodeficiency virus type 1 (HIV-1) protease is a homodimeric aspartyl endopeptidase that is required for virus replication. A number of specific, active-site inhibitors for this enzyme have been described. Many of the inhibitors exhibit significant differences in activity against the HIV-1 and HIV type 2 (HIV-2) enzymes. An initial study was conducted to ascertain the HIV-1 protease's potential to lose sensitivity to several test inhibitors while retaining full enzymatic activity. The substrate binding sites of the HIV-1 and HIV-2 enzymes are almost fully conserved, except for four amino acid residues at positions 32, 47, 76, and 82. Accordingly, recombinant mutant type 1 proteases were constructed that contained the cognate type 2 residue at each of these four positions. The substitution at position 32 resulted in a significant adverse effect on inhibitor potency. However, this substitution also mediated a noted increase in the Km of the substrate. Individual substitutions at the remaining three positions, as well as a combination of all four substitutions, had very little effect on enzyme activity or inhibitor susceptibility. Hence, the four studied active site residues are insufficient to be responsible for differences in inhibitor sensitivity between the HIV-1 and HIV-2 proteases and are unlikely to contribute to the generation of inhibitor-resistant mutant HIV-1 protease.
Asunto(s)
Aminoácidos/genética , Inhibidores de la Proteasa del VIH/farmacología , Proteasa del VIH/genética , Benzopiranos/farmacología , Sitios de Unión/genética , Clonación Molecular , Gráficos por Computador , Farmacorresistencia Microbiana , Escherichia coli/genética , Proteasa del VIH/metabolismo , Inhibidores de la Proteasa del VIH/química , Isoquinolinas/farmacología , Cinética , Modelos Moleculares , Morfolinas/farmacología , Péptidos/farmacología , Quinolinas/farmacología , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Saquinavir , Valina/análogos & derivados , Valina/farmacologíaRESUMEN
The nonnucleoside reverse transcriptase (RT) inhibitors are structurally diverse compounds that are specific inhibitors of the human immunodeficiency virus type 1 RT enzyme. The compounds are largely functionally identical and bind to a common site in the enzyme. HIV-1 variants that exhibit reduced susceptibility to these inhibitors have been derived in cell culture and, more recently, from HIV-1-infected patients undergoing experimental therapy. The variants express amino acid substitutions at RT positions that apparently interact directly with the inhibitors. Effects of specific substitutions at these positions vary among the compounds, suggesting subtle differences in how the compounds physically interact with the enzyme.
Asunto(s)
Antivirales/farmacología , Variación Genética , VIH-1/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa , Benzodiazepinas/farmacología , Benzoxazoles/farmacología , Ensayos Clínicos como Asunto , Farmacorresistencia Microbiana/genética , Infecciones por VIH/tratamiento farmacológico , Transcriptasa Inversa del VIH , VIH-1/genética , Humanos , Imidazoles/farmacología , Nevirapina , Piridinas/farmacología , Piridonas/farmacología , ADN Polimerasa Dirigida por ARN/genéticaAsunto(s)
Antivirales/farmacología , Ácido Aspártico Endopeptidasas/química , Simulación por Computador , Farmacorresistencia Microbiana , Modelos Moleculares , Conformación Proteica , Proteínas de los Retroviridae/química , Retroviridae/efectos de los fármacos , Secuencia de Aminoácidos , Antivirales/química , Ácido Aspártico Endopeptidasas/antagonistas & inhibidores , Ácido Aspártico Endopeptidasas/genética , Sitios de Unión , Proteasa del VIH/química , Proteasa del VIH/genética , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/efectos de los fármacos , VIH-1/enzimología , VIH-2/efectos de los fármacos , VIH-2/enzimología , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Unión Proteica , Retroviridae/genética , Proteínas de los Retroviridae/antagonistas & inhibidores , Proteínas de los Retroviridae/genética , Programas Informáticos , Especificidad por SustratoRESUMEN
The nonnucleoside reverse transcriptase (RT) inhibitors comprise a class of structurally diverse compounds that are functionally related and specific for the human immunodeficiency virus type 1 RT. Viral variants resistant to these compounds arise readily in cell culture and in treated, infected human. Therefore, the eventual clinical usefulness of the nonnucleoside inhibitors will rely on a thorough understanding of the genetic and biochemical bases for resistance. A study was performed to assess the effects of substitutions at each RT amino acid residue that influences the enzyme's susceptibility to the various nonnucleoside compounds. Single substitutions were introduced into both purified enzyme and virus. The resulting patterns of resistance were markedly distinct for each of the tested inhibitors. For instance, a > 50-fold loss of enzyme susceptibility to BI-RG-587 was engendered by any of four individual substitutions, while the same level of relative resistance to the pyridinone derivatives was mediated only by substitution at residue 181. Similarly, substitution at residue 181. Similarly, substitution at residue 106 had a noted effect on virus resistance to BI-RG-587 but not to the pyridinones. The opposite effect was mediated by a substitution at residue 179. Such knowledge of nonucleoside inhibitor resistance profiles may help in understanding the basis for resistant virus selection during clinical studies of these compounds.
Asunto(s)
Antivirales/farmacología , VIH-1/genética , Mutación/genética , Nucleósidos/farmacología , ADN Polimerasa Dirigida por ARN/genética , Inhibidores de la Transcriptasa Inversa , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Antivirales/uso terapéutico , Benzoxazoles/uso terapéutico , ADN Viral/genética , Variación Genética , Transcriptasa Inversa del VIH , VIH-1/enzimología , Humanos , Piridonas/uso terapéutico , Relación Estructura-ActividadRESUMEN
Pyridinone derivatives are potent and specific inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and HIV-1 replication in cell culture. However, the potential clinical usefulness of these compounds as monotherapeutic agents may be limited by the selection of inhibitor-resistant viral variants. Resistance in cell culture is due primarily to mutational alterations at RT amino acid residues 103 and 181. A recombinant HIV-1 RT containing both of these mutations was used to screen a panel of pyridinone analogs for inhibitory activity. L-696,229 and L-697,661, pyridinones currently undergoing clinical evaluation, were more than 4,000-fold weaker against the mutant enzyme than against the wild-type enzyme. In contrast, one derivative of L-696,229, L-702,019 (3-[2-(4,7-dichlorobenzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyrid in-2(1H)-thione), showed only three-fold different potencies against the two enzymes. L-702,019 was also a potent inhibitor of the replication of mutant HIV-1 containing the individual mutations at amino acid 103 or 181 as well as of clinical isolates resistant to L-697,661 and L-696,229. Isolation and analysis of resistant viral variants in cell culture showed that significant resistance to L-702,019 could be engendered only by multiple amino acid substitutions in RT. Accordingly, these studies demonstrated the potential of identifying second-generation specific HIV-1 RT inhibitors that can overcome the viral resistance selected by the first generation of inhibitors.
Asunto(s)
Antivirales/farmacología , Benzoxazoles/farmacología , VIH-1/efectos de los fármacos , VIH-1/enzimología , Piridonas/análogos & derivados , Piridonas/farmacología , Inhibidores de la Transcriptasa Inversa , Antivirales/síntesis química , Farmacorresistencia Microbiana , Transcriptasa Inversa del VIH , VIH-1/genética , Humanos , ADN Polimerasa Dirigida por ARN/genética , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genéticaRESUMEN
Several novel, structurally distinct classes of specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) nonnucleoside inhibitors have been described recently. These include the pyridinone derivatives L-697,639, L-697,661, and L-696,229 as well as BI-RG-587 and the tetrahydroimidazo[4,5,1-j,k]-benzodiazepin-2(1H)-one and -thione compounds. Previous studies have implicated involvement of the RT amino acid residues at positions 103, 181, and 188 in the activity of the compounds. Accordingly, HIV-1 RT mutants containing a series of amino acid substitutions at these positions were constructed. The relative resistance of purified mutant enzymes to each of the inhibitors was assessed. This analysis established the functional equivalence of the three inhibitor classes and provided evidence for the interaction of the 103 site with the 181/188 region. Amino acid substitutions at these positions were also found to influence RT sensitivity to inhibition by phosphonoformate, thereby suggesting a close association between this pyrophosphate analog's binding site in RT and the binding site of the nonnucleoside inhibitors. In addition, aromatic stacking of the amino acid side groups at residues 181 and 188 was suggested to be required for inhibitor activity.
Asunto(s)
Antivirales/farmacología , VIH-1/efectos de los fármacos , VIH-1/enzimología , Inhibidores de la Transcriptasa Inversa , Secuencia de Aminoácidos , Azepinas/farmacología , Benzodiazepinas/farmacología , Benzoxazoles/farmacología , Farmacorresistencia Microbiana/genética , Transcriptasa Inversa del VIH , Imidazoles/farmacología , Cinética , Mutagénesis Sitio-Dirigida , Nevirapina , Piridinas/farmacología , Piridonas/farmacología , ADN Polimerasa Dirigida por ARN/genética , ADN Polimerasa Dirigida por ARN/aislamiento & purificación , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/aislamiento & purificación , Relación Estructura-ActividadRESUMEN
The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is potently inhibited by a structurally diverse group of nonnucleoside compounds. These include pyridinone derivatives, tetrahydroimadazo[4,5,1-j,k][1,4]-benzodiazepin-2(1H)-one and -thione, and BI-RG-587 (nevirapine). The compounds act noncompetitively, by an unknown mechanism, with respect to template-primer and nucleotide substrates. Despite a high degree of similarity between the HIV-1 and HIV-2 RTs, the HIV-2 enzyme is totally insensitive to these inhibitors. Using a novel method for joining DNA sequences, we have exploited this difference between the two enzymes to identify the regions of the RT that contribute to the compounds' inhibitory activities. The relative in vitro sensitivities of HIV-1/HIV-2 chimeric and site-specific mutant enzymes were determined. Sensitivity to inhibition was largely, though not exclusively, dependent upon the RT region defined by amino acid residues 176 to 190, with specific contributions by residues 181 and 188. The region defined by residues 101 to 106 was found to functionally interact with the domain from 155 to 217. In addition, the functional equivalence of the three inhibitor groups was shown.
Asunto(s)
Antivirales/farmacología , Azepinas/farmacología , Benzodiazepinas/farmacología , Benzoxazoles/farmacología , VIH-1/enzimología , Imidazoles/farmacología , Piridinas/farmacología , Piridonas/farmacología , Inhibidores de la Transcriptasa Inversa , Farmacorresistencia Microbiana , Escherichia coli/efectos de los fármacos , Escherichia coli/enzimología , Transcriptasa Inversa del VIH , Humanos , Nevirapina , FenotipoRESUMEN
Bacterially expressed Tat protein of human immunodeficiency virus type 1 binds selectively to short RNA transcripts containing the viral transactivation-responsive element (TAR). Sequences sufficient for Tat interaction map to the distal portion of the TAR stem-loop. We show that critical sequences for Tat binding are located in the single-stranded "bulge," but no requirement for specific "loop" sequences could be demonstrated. TAR RNA competed for complex formation, and TAR mutants exhibited up to 10-fold reduced affinity for Tat. Synthetic peptides containing the basic region of Tat bound selectively to TAR RNA and exhibited the same sequence requirements and similar relative affinities for mutant TAR RNA as the intact protein. These results suggest that Tat contains a small RNA-binding domain capable of recognizing TAR and implicate functional relevance for direct Tat-TAR interaction in transactivation.
Asunto(s)
Productos del Gen tat/metabolismo , Duplicado del Terminal Largo de VIH/genética , VIH-1/genética , Secuencias Reguladoras de Ácidos Nucleicos , Secuencia de Aminoácidos , Unión Competitiva , Análisis Mutacional de ADN , Técnicas In Vitro , Datos de Secuencia Molecular , Péptidos/síntesis química , Péptidos/metabolismo , ARN Viral/genética , ARN Viral/metabolismo , Proteínas Recombinantes , Relación Estructura-Actividad , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
A series of synthetic peptides representing authentic proteolytic cleavage sites of human rhinovirus type 14 were assayed as substrates for purified 3C protease. Competition cleavage assays were employed to determine the relative specificity constants (Kcat/Km) for substrates with sequences related to the viral 2C-3A cleavage site. Variable length peptides representing the 2C-3A cleavage site were cleaved with comparable efficiency. These studies defined a minimum substrate of 6 amino acids (TLFQ/GP), although retention of the residue at position P5 (ETLFQ/GP) resulted in a better substrate by an order of magnitude. Amino acid substitutions at position P5, P4, P1', or P2' indicated that the identity of the residue at position P5 was not critical, whereas substitutions at position P4, P1' or P2' resulted in substrates with Kcat/Km values varying over 2 orders of magnitude. In contrast to the 2C-3A cleavage site, small peptide derivatives representative of the 3A-3B cleavage site were relatively poor substrates, which suggested that residues flanking the minimum core sequence may influence susceptibility to cleavage. The 3C protease of rhinovirus type 14 was also capable of cleaving peptides representing comparable cleavage sites predicted for coxsackie B virus and poliovirus.
Asunto(s)
Cisteína Endopeptidasas/metabolismo , Rhinovirus/enzimología , Proteínas Virales , Proteasas Virales 3C , Secuencia de Aminoácidos , Unión Competitiva , Datos de Secuencia Molecular , Relación Estructura-Actividad , Especificidad por SustratoRESUMEN
Human rhinoviruses are the major causative agents of the common cold in humans and have been divided into major and minor groups based on receptor specificity. cDNAs encoding the light and heavy chains of a murine monoclonal antibody that recognizes the major group receptor were cloned, abundantly expressed in Escherichia coli, and renatured into Fab fragments that blocked virus binding and protected HeLa cell monolayers from rhinovirus infection. Elimination of the cysteines normally bridging the heavy and light chains yielded molecules indistinguishable from wild-type Fab fragments in virus binding assays. Single-chain antibodies with covalently linked light and heavy variable domains were also expressed and showed receptor binding and cell protection activities. These recombinant antibody fragments are potentially useful in preventing or treating common colds in humans.